Currently Enrolling Trials
Xeloda (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity.
Xeloda is specifically indicated for:
- Adjuvant Colon Cancer – Patients with Dukes’ C colon cancer
- Metastatic Colorectal Cancer - First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred
- Metastatic Breast Cancer
- – In combination with docetaxel after failure of prior anthracycline containing therapy
- – As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen
BC: The approval of Xeloda was based on a study involving 43 patients whose cancer no longer responded to conventional treatment. In that group, Xeloda appeared to help shrink tumors in 25% of patients. In a larger study of 162 patients whose cancer was resistant to normal treatment, tumors shrank by half in almost 20%.
CRC: The FDA's approval of Xeloda was based on results from two multi-national phase III trials involving 1,200 subjects with metastatic colorectal cancer. Results showed that Xeloda shrank tumors more effectively than a standard care of intravenous fluorouracil and leucovorin, known as the Mayo Regimen. One trial reported overall response rates to Xeloda as being more than double those to the Mayo Regimen, while in the other, the response to Xeloda was 30% greater than that to the intravenous therapy.
Adverse events associated with the use of capecitabine may include (but are not limited to) the following:
- Hand-and-foot syndrome